Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.


TSX:CPH - Post by User

Comment by pabalooon Jan 05, 2021 7:12pm
146 Views
Post# 32229655

RE:RE:RE:RE:RE:RE:Takeover talks with Bausch Health?

RE:RE:RE:RE:RE:RE:Takeover talks with Bausch Health?Totally agree Craig has no interest in giving away the company at a discount. Good for him Bausch can suck his big toe if they think there garbage gets them an easy deal. Trulance is worth 25 million Cipher has 10 in it they can pay the premium or watch Cipher mismanage its sales with no sales force in place or coming. Laughable that they still have such a high market share for Epuris really.  Cipher will have .50 in cash soon with zero debt. Add Trulance,  Epuris and Absorica we could be making .20 cents a quarter and Trevyent should be okayed by the fda by June. Still believe Bausch is on the hook for 4 million in the arbitration settlement. We'll find out shortly.
<< Previous
Bullboard Posts
Next >>